Sarah M Brooker, Jacopo Pasquini, Seung Ho Choi, David-Erick Lafontant, Seyed-Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta M Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly N H Nudelman, Andrew Siderowf, Caroline M Tanner, Thomas F Tropea, Tatiana Foroud, Lana M Chahine, Brit Mollenhauer, Kalpana M Merchant, Douglas Galasko, Christopher S Coffey, Roseanne D Dobkin, Ethan G Brown, Roy N Alcalay, Daniel Weintraub, Kenneth Marek, Tanya Simuni, Paulina Gonzalez-Latapi, Nicola Pavese, Kathleen L Poston, Parkinson's Progression Markers Initiative,
BACKGROUND: The cerebrospinal fluid alpha-synuclein seed amplification assay (CSFasynSAA) detects alpha-synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
